Glioblastoma
Conditions
Interventions
experimental group:Nimotuzumab Combined with Intensity Modulated Radiotherapy and Temozolamide Chemotherapy
Sponsors
The Third Hospital of Peking University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-70 years; 2. Patients with KPS >= 60; 3. GBM was confirmed by histopathology; 4. Patients whose interval from initial diagnosis to admission is less than 4 weeks; 5. According to the gender distribution of GBM, the ratio of female to male was 2:3; 6. Patients with sufficient blood volume (within 14 days before treatment); 7. Neutrophil count >= 1500 / mm3 or leukocyte count >= 2000 / mm3; 8. Platelet >= 100.00/mm3; 9. Hemoglobin >= 10g / dl; 10. Bun 12 weeks; 14. Patients willing to sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have received brain radiotherapy or DTIC (dacarbazine) or TMZ (temozolomide) chemotherapy; 2. Patients who are known to be allergic to exogenous protein; 3. Patients who have received chemotherapy or EGFR inhibitors; 4. Patients who have received antibody treatment; 5. Patients who did not recover from the acute toxicity of previous treatment; 6. Patients with acute infection requiring antibiotic treatment; 7. Patients who are forbidden to TMZ due to frequent vomiting or other physical conditions; 8. Patients with clinically active hepatorenal or cardiac diseases; 9. Patients who have known other cancers for less than 5 years (excluding cervical carcinoma in situ, basal cell carcinoma and skin squamous cell carcinoma); 10. HIV patients; 11. Pregnant or lactating women; 12. Patients participating in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety;complication; | — |
Secondary
| Measure | Time frame |
|---|---|
| os;pfs;life quality; | — |
Countries
China
Contacts
Public ContactSuqing Tian
The Third Hospital of Peking University
Outcome results
None listed